3/23
09:14 am
pcvx
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults [Yahoo! Finance]
Low
Report
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults [Yahoo! Finance]
3/23
08:30 am
pcvx
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Low
Report
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
3/18
07:34 pm
pcvx
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Low
Report
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
3/10
03:02 pm
pcvx
Vaxcyte (PCVX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Vaxcyte (PCVX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
3/3
02:24 am
pcvx
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]
Medium
Report
Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte's VAX-31 Shift the Bull Case (PCVX)? [Yahoo! Finance]
3/2
06:53 pm
pcvx
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. [Yahoo! Finance]
Medium
Report
Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock. [Yahoo! Finance]
3/2
02:28 am
pcvx
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists [Yahoo! Finance]
Low
Report
Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap Persists [Yahoo! Finance]
3/1
10:52 pm
pcvx
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds [Yahoo! Finance]
Low
Report
A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum Rebuilds [Yahoo! Finance]
2/26
07:22 am
pcvx
Vaxcyte, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Medium
Report
Vaxcyte, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
2/25
07:05 pm
pcvx
Vaxcyte (PCVX) had its "buy" rating reaffirmed by BTIG Research.
Medium
Report
Vaxcyte (PCVX) had its "buy" rating reaffirmed by BTIG Research.
2/25
12:27 am
pcvx
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... [Yahoo! Finance]
Medium
Report
Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ... [Yahoo! Finance]
2/24
04:05 pm
pcvx
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Low
Report
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
2/19
03:53 am
pcvx
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials [Yahoo! Finance]
Low
Report
Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine Trials [Yahoo! Finance]
2/18
07:46 pm
pcvx
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating [Yahoo! Finance]
Low
Report
Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald Rating [Yahoo! Finance]
2/16
12:38 pm
pcvx
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) [Yahoo! Finance]
Low
Report
Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX) [Yahoo! Finance]
2/15
05:24 pm
pcvx
Should Vaxcyte's OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors? [Yahoo! Finance]
Low
Report
Should Vaxcyte's OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors? [Yahoo! Finance]
2/11
04:05 pm
pcvx
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
Low
Report
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines
2/10
04:23 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 [Yahoo! Finance]
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 [Yahoo! Finance]
2/10
04:05 pm
pcvx
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
Low
Report
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026
2/5
04:05 pm
pcvx
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
Medium
Report
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit
2/2
08:36 pm
pcvx
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]
Low
Report
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus [Yahoo! Finance]
2/2
04:44 pm
pcvx
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
Low
Report
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares [Yahoo! Finance]
2/2
04:05 pm
pcvx
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Low
Report
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2/2
10:01 am
pcvx
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.
Medium
Report
Vaxcyte (NASDAQ:PCVX) had its "buy" rating reaffirmed by analysts at Guggenheim. They now have a $116.00 price target on the stock.
1/30
07:12 pm
pcvx
Vaxcyte Announces Pricing of $550 Million Public Offering [Yahoo! Finance]
Medium
Report
Vaxcyte Announces Pricing of $550 Million Public Offering [Yahoo! Finance]